for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-AstraZeneca reports data from study on Tagrisso

Dec 9 (Reuters) -

* AstraZeneca says Tagrisso reduced risk of disease progression by 70 percent and improved progression-free survival by almost six months

* AstraZeneca says data showed Tagrisso offered a statistically-significant improvement in PFS versus standard platinum-based doublet chemotherapy

* Reports data from Aura3 Phase III trial on Tagrisso Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up